spacer
home > ict > spring 2006 > strategic interaction
PUBLICATIONS
International Clinical Trials

Strategic Interaction

Approaching ‘eClinical’ as a new philosophy for clinical trial management, Ian O’Shaughnessy at ICON Clinical Research believes that with the correct strategy the transition to eClinical trials can be managed effectively

The adoption of internet technology and electronic media to support clinical research and the management of clinical trials has been one of the most significant changes in the pharmaceutical industry over the last five years. A new way of working, commonly termed ‘eClinical’, has emerged based on technologies that enable electronic data capture (EDC). While the pace of this change is accelerating, the significant challenge of managing the transition to eClinical trials still remains at the operational level within organisations.

MANAGING INDUSTRY ATTITUDES AND PERCEPTIONS

Across the clinical research industry, misconceptions – primarily among those who have not been directly impacted by its use – have affected the early implementation of eClinical, and, in order to make the transition a successful one, significant education is required to address such perceptions. The first misconception to address is the belief that eClinical as a business approach should be driven purely by technology specialists and data managers. The second is that eClinical and EDC are merely technological solutions rather than an entirely new way of conducting clinical trials that will impact on all those involved. However, implemented in its entirety, eClinical marks a significant, if not complete, change in the approach to conducting clinical research trials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Ian O’Shaughnessy is a Project Manager in Data Management at ICON Clinical Research in Ireland. He has worked in the industry for 10 years and has been with ICON since 2002, working in both data management and database programming. He currently leads a team of data managers working on eClinical Trials. Ian was educated at Trinity College Dublin where he was awarded a Bachelor of Arts with Honours in Genetics in 1996. In 1999, he obtained a Postgraduate Diploma in Business Studies and Information Technology.
spacer
Ian O’Shaughnessy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.
More info >>

White Papers
 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement